Evidence map›Paper›PMID 40369482›Full record

ArticleBMC cancer2025

Comprehensive network pharmacology and experimentation to unveil the therapeutic efficacy and mechanisms of gypenoside LI in anaplastic thyroid cancer.

Meiyu Liu, Haidong Liao, Qin Peng, Junwei Huang, Weixiang Liu, Mengqiao Dai, Zanbing Li, Yang Xie, Jiafeng Liu, Yong Ying and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Therapeutic Potential ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meiyu LiuDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Haidong LiaoDepartment of General Surgery, First People's Hospital of Longnan, Longnan, Jiangxi, 341706, China.
Qin PengDepartment of Pathology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Junwei HuangDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Weixiang LiuDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Mengqiao DaiInstitute of Thyroid Diseases of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Zanbing LiDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Yang XieDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Jiafeng LiuInstitute of Thyroid Diseases of Gannan Medical University, Ganzhou, Jiangxi, 341000, China.
Yong YingGanzhou Key Laboratory of Thyroid Cancer, Ganzhou, Jiangxi, 341000, China. 435134372@qq.com.
Xiangtai ZengDepartment of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China. xiangtai.zeng@gmu.edu.cn.

Funding

Ganzhou Key Laboratory of Thyroid Tumors 20220101-24Project of Science and Technology Program of Jiangxi Province Chinese Medicine for 2023 2023B0202The National Natural Science Foundation of China 82460498
6 · The paper itself

Abstract

backgroundAnaplastic thyroid cancer (ATC) is a markedly invasive subtype of thyroid cancer with a poor prognosis. The Gynostemma pentaphyllum-derived Gypenoside LI (Gyp LI) can inhibit the growth and metastasis of various tumors. This study was designed to evaluate the pharmacological mechanisms of Gyp LI against ATC via network pharmacology analysis combined with experimental verification.

methodsCore targets and signaling pathways were obtained by using the network pharmacological analysis method. Utilizing a combination of in vitro and in vivo methodologies, we conducted a rigorous examination to ascertain the suppressive impact of Gyp LI on the ATC cell lines, specifically 8305 C and C643. Then used western blotting and immunohistochemistry to analyze the inhibitory effects of Gyp LI on SRC kinase and its downstream signaling pathways.

resultsThrough integrative analysis of Gyp LI and ATC-target interactions, 78 candidate targets were identified. Network-based protein-protein interaction (PPI) analysis, combined with molecular docking, pinpointed HSP90AA1, SRC, and CASP3 as pivotal hub genes modulated by Gyp LI. KEGG enrichment analysis further emphasized the PI3K/AKT pathway, highlighting its critical involvement in ATC therapy. Gyp LI significantly inhibits ATC cell proliferation, migration, and invasion while inducing apoptosis, likely via modulation of the SRC/PI3K/AKT axis. Moreover, it enhances iodine uptake in ATC cells by regulating the sodium-iodide symporter pathway.

conclusionsGyp LI effectively inhibits ATC progression by modulating SRC/PI3K/AKT signaling, enhancing apoptosis, and promoting iodine uptake, offering potential therapeutic benefits for ATC treatment.

Indexed as

Network PharmacologyThyroid Carcinoma, AnaplasticThyroid NeoplasmsAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGynostemmaHumansMiceMolecular Docking SimulationPlant ExtractsProtein Interaction MapsSignal TransductiongypenosidePlant Extractssrc-Family KinasesAnaplastic thyroid cancerGypenoside LIIodine uptakeNetwork pharmacologySRC/ PI3K/AKT signaling pathway

Identifiers

PMID40369482
PMCPMC12076972

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.